{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:10:26Z","timestamp":1790982626518,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Young Scientists Fund of the National Natural Science Foundation of China","award":["82103916"],"award-info":[{"award-number":["82103916"]}]},{"name":"the General Program of the National Natural Science Foundation of China General Project","award":["81970633"],"award-info":[{"award-number":["81970633"]}]},{"name":"the Major public welfare special projects in Henan Province","award":["201300310600"],"award-info":[{"award-number":["201300310600"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sodium\u2013glucose cotransporter 2 inhibitors (SGLT2i) are recommended for type 2 diabetes mellitus patients with impaired renal function, but the actual situation of SGLT2i using is unclear. Therefore, in this real-world study, we analyzed the treatment scheme and clinical characteristics of SGLT2i in patients with diabetic kidney disease (DKD). We included DKD patients hospitalized in the First Affiliated Hospital of Zhengzhou University from October 2017 to March 2020. The Apriori algorithm of association rules was used to analysis treatment scheme prescribing SGLT2i and other different combinations of hypoglycemic drugs. SGLT2i was used in 781 (12.3%) of 6336 DKD patients, both number and proportion of patients using SGLT2i increased from 2017 to 2020 (1.9% to 33%). Nighty-eight percent of all DKD patients using SGLT2i were combined with other glucose-lowering agents, and insulin, metformin and alpha-glucosidase inhibitors are most commonly used in combination with hypoglycemic drugs. Multivariate analysis showed that compared with non-SGLT2i group, patients using SGLT2i were associated with younger age, higher BMI, higher HbA1c, preserved kidney function, dyslipidemia and combined with ACEI\/ARB and statins. In this real-world study, use of SGLT2i in DKD patients is still low. Most patients performed younger age and in the early stages of chronic kidney disease with poor glycemic control. Clinical inertia should be overcome to fully exert the cardiorenal protective effects of SGLT2 inhibitors, with attention to rational drug use.<\/jats:p>","DOI":"10.1038\/s41598-023-33211-1","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T13:03:21Z","timestamp":1681304601000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Integrated analysis for treatment scheme of sodium\u2013glucose cotransporter 2 inhibitors in patients with diabetic kidney disease: a real-world study"],"prefix":"10.1038","volume":"13","author":[{"given":"Li","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangpu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiancheng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangsuo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"33211_CR1","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.2337\/dc14-1296","volume":"37","author":"KR Tuttle","year":"2014","unstructured":"Tuttle, K. R. et al. Diabetic kidney disease: A report from an ADA Consensus Conference. Diabetes Care 37, 2864\u20132883. https:\/\/doi.org\/10.2337\/dc14-1296 (2014).","journal-title":"Diabetes Care"},{"key":"33211_CR2","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic, R. Z., Rooney, M. T. & Tuttle, K. R. Diabetic kidney disease: Challenges, progress, and possibilities. Clin. J. Am. Soc. Nephrol. 12, 2032\u20132045. https:\/\/doi.org\/10.2215\/CJN.11491116 (2017).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"33211_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/dom.14251","volume":"23","author":"CM Khoo","year":"2021","unstructured":"Khoo, C. M. et al. Use of sodium\u2013glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations. Diabetes Obes. Metab. 23, 299\u2013317. https:\/\/doi.org\/10.1111\/dom.14251 (2021).","journal-title":"Diabetes Obes. Metab."},{"key":"33211_CR4","doi-asserted-by":"publisher","first-page":"111918","DOI":"10.1016\/j.biopha.2021.111918","volume":"141","author":"J Wang","year":"2021","unstructured":"Wang, J., Xiang, H., Lu, Y., Wu, T. & Ji, G. New progress in drugs treatment of diabetic kidney disease. Biomed. Pharmacother. 141, 111918. https:\/\/doi.org\/10.1016\/j.biopha.2021.111918 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"33211_CR5","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925 (2017).","journal-title":"N. Engl. J. Med."},{"key":"33211_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389 (2019).","journal-title":"N. Engl. J. Med."},{"key":"33211_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner, C. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323\u2013334. https:\/\/doi.org\/10.1056\/NEJMoa1515920 (2016).","journal-title":"N. Engl. J. Med."},{"key":"33211_CR8","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744 (2019).","journal-title":"N. Engl. J. Med."},{"key":"33211_CR9","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816 (2020).","journal-title":"N. Engl. J. Med."},{"key":"33211_CR10","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","volume":"98","author":"Kidney Disease: Improving Global Outcomes Diabetes Work, G","year":"2020","unstructured":"Kidney Disease: Improving Global Outcomes Diabetes Work, G. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 98, S1\u2013S115. https:\/\/doi.org\/10.1016\/j.kint.2020.06.019 (2020).","journal-title":"Kidney Int."},{"key":"33211_CR11","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.2337\/dc20-0120","volume":"43","author":"TM Caparrotta","year":"2020","unstructured":"Caparrotta, T. M. et al. Prescribing paradigm shift? Applying the 2019 European Society of Cardiology-led guidelines on diabetes, prediabetes, and cardiovascular disease to assess eligibility for sodium\u2013glucose cotransporter 2 inhibitors or glucagon-like peptide 1 receptor agonists as first-line monotherapy (or add-on to metformin monotherapy) in type 2 diabetes in Scotland. Diabetes Care 43, 2034\u20132041. https:\/\/doi.org\/10.2337\/dc20-0120 (2020).","journal-title":"Diabetes Care"},{"key":"33211_CR12","doi-asserted-by":"publisher","first-page":"921","DOI":"10.2337\/dc19-1943","volume":"43","author":"CV Dave","year":"2020","unstructured":"Dave, C. V., Schneeweiss, S., Wexler, D. J., Brill, G. & Patorno, E. Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013\u20132018. Diabetes Care 43, 921\u2013924. https:\/\/doi.org\/10.2337\/dc19-1943 (2020).","journal-title":"Diabetes Care"},{"key":"33211_CR13","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2337\/dc21-1815","volume":"45","author":"D Mahtta","year":"2022","unstructured":"Mahtta, D. et al. Utilization rates of SGLT2 inhibitors and GLP-1 receptor agonists and their facility-level variation among patients with atherosclerotic cardiovascular disease and type 2 diabetes: Insights from the department of veterans affairs. Diabetes Care 45, 372\u2013380. https:\/\/doi.org\/10.2337\/dc21-1815 (2022).","journal-title":"Diabetes Care"},{"key":"33211_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","volume":"8","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L. et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): A multinational observational cohort study. Lancet Diabetes Endocrinol. 8, 27\u201335. https:\/\/doi.org\/10.1016\/S2213-8587(19)30384-5 (2020).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"33211_CR15","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","volume":"6","author":"V Perkovic","year":"2018","unstructured":"Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes: Results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 6, 691\u2013704. https:\/\/doi.org\/10.1016\/S2213-8587(18)30141-4 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"33211_CR16","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/s2213-8587(19)30180-9","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon, O. et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: An analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 7, 606\u2013617. https:\/\/doi.org\/10.1016\/s2213-8587(19)30180-9 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"33211_CR17","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.2337\/dc19-S011","volume":"42","author":"American Diabetes, A","year":"2019","unstructured":"American Diabetes, A. 11. Microvascular complications and foot care: Standards of medical care in diabetes-2019. Diabetes Care 42, S124\u2013S138. https:\/\/doi.org\/10.2337\/dc19-S011 (2019).","journal-title":"Diabetes Care"},{"key":"33211_CR18","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1016\/j.jacc.2018.08.2202","volume":"72","author":"M Vaduganathan","year":"2018","unstructured":"Vaduganathan, M. et al. Prescriber patterns of SGLT2i after expansions of U.S. food and drug administration labeling. J. Am. Coll. Cardiol. 72, 3370\u20133372. https:\/\/doi.org\/10.1016\/j.jacc.2018.08.2202 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"33211_CR19","unstructured":"Administration, FDA. FDA Drug Safety Communication, https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm500965.htm."},{"key":"33211_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2022.3839","author":"MG Nanna","year":"2023","unstructured":"Nanna, M. G., Kolkailah, A. A., Page, C., Peterson, E. D. & Navar, A. M. Use of sodium\u2013glucose cotransporter 2 inhibitors and glucagonlike peptide-1 receptor agonists in patients with diabetes and cardiovascular disease in community practice. JAMA Cardiol. https:\/\/doi.org\/10.1001\/jamacardio.2022.3839 (2023).","journal-title":"JAMA Cardiol."},{"key":"33211_CR21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.6139","author":"LA Eberly","year":"2021","unstructured":"Eberly, L. A. et al. Association of race\/ethnicity, gender, and socioeconomic status with sodium\u2013glucose cotransporter 2 inhibitor use among patients with diabetes in the US. JAMA Netw. Open https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.6139 (2021).","journal-title":"JAMA Netw. Open"},{"key":"33211_CR22","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1111\/j.1464-5491.2008.02592.x","volume":"25","author":"H Yokoyama","year":"2008","unstructured":"Yokoyama, H., Oishi, M., Kawai, K., Sone, H., Japan Diabetes Clinical Data Management Study, G. Reduced GFR and microalbuminuria are independently associated with prevalent cardiovascular disease in type 2 diabetes: JDDM study 16. Diabet. Med. 25, 1426\u20131432. https:\/\/doi.org\/10.1111\/j.1464-5491.2008.02592.x (2008).","journal-title":"Diabet. Med."},{"key":"33211_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12933-020-01154-w","volume":"19","author":"G Schernthaner","year":"2020","unstructured":"Schernthaner, G. et al. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc. Diabetol. 19, 185. https:\/\/doi.org\/10.1186\/s12933-020-01154-w (2020).","journal-title":"Cardiovasc. Diabetol."},{"key":"33211_CR24","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.2337\/dc19-S011","volume":"42","author":"M Complications","year":"2019","unstructured":"Complications, M. & Care, F. Standards of medical care in diabetes-2019. Diabetes Care 42, S124-s138. https:\/\/doi.org\/10.2337\/dc19-S011 (2019).","journal-title":"Diabetes Care"},{"key":"33211_CR25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.pcd.2020.10.002","volume":"15","author":"A Tumminia","year":"2021","unstructured":"Tumminia, A., Graziano, M., Vinciguerra, F., Lomonaco, A. & Frittita, L. Efficacy, renal safety and tolerability of sodium\u2013glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes: A real-world experience. Prim. Care Diabetes 15, 283\u2013288. https:\/\/doi.org\/10.1016\/j.pcd.2020.10.002 (2021).","journal-title":"Prim. Care Diabetes"},{"key":"33211_CR26","doi-asserted-by":"publisher","first-page":"S168","DOI":"10.2337\/dc21-S012","volume":"44","author":"American Diabetes, A","year":"2021","unstructured":"American Diabetes, A. 12. Older adults: Standards of medical care in diabetes-2021. Diabetes Care 44, S168\u2013S179. https:\/\/doi.org\/10.2337\/dc21-S012 (2021).","journal-title":"Diabetes Care"},{"key":"33211_CR27","doi-asserted-by":"publisher","first-page":"e0229621","DOI":"10.1371\/journal.pone.0229621","volume":"15","author":"JS Knudsen","year":"2020","unstructured":"Knudsen, J. S. et al. Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study. PLoS ONE 15, e0229621. https:\/\/doi.org\/10.1371\/journal.pone.0229621 (2020).","journal-title":"PLoS ONE"},{"key":"33211_CR28","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1111\/obr.12755","volume":"19","author":"PC Lee","year":"2018","unstructured":"Lee, P. C., Ganguly, S. & Goh, S. Y. Weight loss associated with sodium\u2013glucose cotransporter-2 inhibition: A review of evidence and underlying mechanisms. Obes. Rev. 19, 1630\u20131641. https:\/\/doi.org\/10.1111\/obr.12755 (2018).","journal-title":"Obes. Rev."},{"key":"33211_CR29","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2337\/dc10-2415%JDiabetesCare","volume":"34","author":"RR Wing","year":"2011","unstructured":"Wing, R. R. et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 34, 1481\u20131486. https:\/\/doi.org\/10.2337\/dc10-2415%JDiabetesCare (2011).","journal-title":"Diabetes Care"},{"key":"33211_CR30","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"A Patel","year":"2008","unstructured":"Patel, A. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560\u20132572. https:\/\/doi.org\/10.1056\/NEJMoa0802987 (2008).","journal-title":"N. Engl. J. Med."},{"key":"33211_CR31","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.2337\/dc20-S009","volume":"43","author":"American Diabetes, A","year":"2019","unstructured":"American Diabetes, A. 9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes\u20142020. Diabetes Care 43, S98\u2013S110. https:\/\/doi.org\/10.2337\/dc20-S009 (2019).","journal-title":"Diabetes Care"},{"key":"33211_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino, F. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. 41, 255\u2013323. https:\/\/doi.org\/10.1093\/eurheartj\/ehz486 (2020).","journal-title":"Eur. Heart J."},{"key":"33211_CR33","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.2337\/dc22-S002","volume":"45","author":"American Diabetes Association Professional Practice, C","year":"2022","unstructured":"American Diabetes Association Professional Practice, C. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2022. Diabetes Care 45, S17\u2013S38. https:\/\/doi.org\/10.2337\/dc22-S002 (2022).","journal-title":"Diabetes Care"},{"key":"33211_CR34","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.2337\/dc20-1231","volume":"43","author":"Y Xie","year":"2020","unstructured":"Xie, Y. et al. Comparative effectiveness of the sodium\u2013glucose cotransporter 2 inhibitor empagliflozin versus other antihyperglycemics on risk of major adverse kidney events. Diabetes Care 43, 2785\u20132795. https:\/\/doi.org\/10.2337\/dc20-1231 (2020).","journal-title":"Diabetes Care"},{"key":"33211_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0547-1","author":"H Zou","year":"2017","unstructured":"Zou, H., Zhou, B. & Xu, G. SGLT2 inhibitors: A novel choice for the combination therapy in diabetic kidney disease. Cardiovasc. Diabetol. https:\/\/doi.org\/10.1186\/s12933-017-0547-1 (2017).","journal-title":"Cardiovasc. Diabetol."},{"key":"33211_CR36","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/dom.12654","volume":"18","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink, H. J., Johnsson, E., Gause-Nilsson, I., Cain, V. A. & Sj\u00f6str\u00f6m, C. D. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes. Metab. 18, 590\u2013597. https:\/\/doi.org\/10.1111\/dom.12654 (2016).","journal-title":"Diabetes Obes. Metab."},{"key":"33211_CR37","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1080\/14740338.2020.1817378","volume":"19","author":"Y Cai","year":"2020","unstructured":"Cai, Y., Shi, W. & Xu, G. The efficacy and safety of SGLT2 inhibitors combined with ACEI\/ARBs in the treatment of type 2 diabetes mellitus: A meta-analysis of randomized controlled studies. Expert Opin. Drug Saf. 19, 1497\u20131504. https:\/\/doi.org\/10.1080\/14740338.2020.1817378 (2020).","journal-title":"Expert Opin. Drug Saf."},{"key":"33211_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.303","author":"S Seidu","year":"2021","unstructured":"Seidu, S., Kunutsor, S. K., Topsever, P. & Khunti, K. Benefits and harms of sodium\u2010glucose co\u2010transporter\u20102 inhibitors (SGLT2\u2010I) and renin\u2013angiotensin\u2013aldosterone system inhibitors (RAAS\u2010I) versus SGLT2\u2010Is alone in patients with type 2 diabetes: A systematic review and meta\u2010analysis of randomized controlled trials. Endocrinol. Diabetes Metab. https:\/\/doi.org\/10.1002\/edm2.303 (2021).","journal-title":"Endocrinol. Diabetes Metab."},{"key":"33211_CR39","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.2337\/dc20-2623","volume":"44","author":"D Giugliano","year":"2021","unstructured":"Giugliano, D. et al. Feasibility of simplification from a basal-bolus insulin regimen to a fixed-ratio formulation of basal insulin plus a GLP-1RA or to basal insulin plus an SGLT2 inhibitor: BEYOND, a randomized, pragmatic trial. Diabetes Care 44, 1353\u20131360. https:\/\/doi.org\/10.2337\/dc20-2623 (2021).","journal-title":"Diabetes Care"},{"key":"33211_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.08.012","author":"IH de Boer","year":"2022","unstructured":"de Boer, I. H. et al. Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. https:\/\/doi.org\/10.1016\/j.kint.2022.08.012 (2022).","journal-title":"Kidney Int."},{"key":"33211_CR41","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s13300-018-0420-6","volume":"9","author":"E Goncalves","year":"2018","unstructured":"Goncalves, E. & Bell, D. S. H. Combination treatment of SGLT2 inhibitors and GLP-1 receptor agonists: Symbiotic effects on metabolism and cardiorenal risk. Diabetes Ther. 9, 919\u2013926. https:\/\/doi.org\/10.1007\/s13300-018-0420-6 (2018).","journal-title":"Diabetes Ther."},{"key":"33211_CR42","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.clinthera.2019.12.012","volume":"42","author":"O Diaz-Trastoy","year":"2020","unstructured":"Diaz-Trastoy, O. et al. GLP1 receptor agonist and SGLT2 inhibitor combination: An effective approach in real-world clinical practice. Clin. Ther. 42, e1\u2013e12. https:\/\/doi.org\/10.1016\/j.clinthera.2019.12.012 (2020).","journal-title":"Clin. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33211-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33211-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33211-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T13:07:22Z","timestamp":1681304842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-33211-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["33211"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-33211-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]},"assertion":[{"value":"28 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5969"}}